Any feedback?
Literature summary for 3.4.23.16 extracted from
- Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease (2008), J. Mol. Biol., 383, 347-357.
Crystallization (Commentary)
| Crystallization (Comment) | Organism |
|---|---|
| mutants I50V and I84 V in complex with inhibitor N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide), to 1.58 A and 1.92 a resolution, respectively | Human immunodeficiency virus 1 |
Protein Variants
| Protein Variants | Comment | Organism |
|---|---|---|
| I50V | analysis of kinetic parameters | Human immunodeficiency virus 1 |
| I84V | analysis of kinetic parameters | Human immunodeficiency virus 1 |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis(benzylsulfamoyl)]dibenzamide | - |
Human immunodeficiency virus 1 |  |
| 4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis[[4-(trifluoromethyl)benzyl]sulfamoyl]]dibenzamide | - |
Human immunodeficiency virus 1 | |
| N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide) | - |
Human immunodeficiency virus 1 | |
| N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide] | - |
Human immunodeficiency virus 1 | |
KM Value [mM]
| KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|
| 0.0052 | - |
Abz-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0097 | - |
Abz-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0146 | - |
Abz-Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg-NH2 | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0227 | - |
Abz-Lys-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0277 | - |
Abz-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0513 | - |
Abz-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0549 | - |
Abz-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0706 | - |
Abz-Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg-NH2 | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.072 | - |
Abz-Lys-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.117 | - |
Abz-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.139 | - |
Abz-Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg-NH2 | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.158 | - |
Abz-Lys-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Human immunodeficiency virus 1 | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| Abz-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 + H2O | - |
Human immunodeficiency virus 1 | Abz-Ala-Arg-Val-Nle + (p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | - |
? | |
| Abz-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 + H2O | - |
Human immunodeficiency virus 1 | Abz-Arg-Val-Nle + (p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | - |
? | |
| Abz-Lys-Ala-Arg-Val-Nle-(p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 + H2O | - |
Human immunodeficiency virus 1 | Abz-Lys-Ala-Arg-Val-Nle + (p-nitro)Phe-Phe-Glu-Ala-Nle-NH2 | - |
? | |
| Abz-Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg-NH2 + H2O | - |
Human immunodeficiency virus 1 | Abz-Thr-Ile-Nle + (p-nitro)Phe-Gln-Arg-NH2 | - |
? | |
Ki Value [mM]
| Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
|---|---|---|---|---|---|
| 0.000036 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis(benzylsulfamoyl)]dibenzamide | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00007 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis[[4-(trifluoromethyl)benzyl]sulfamoyl]]dibenzamide | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00012 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis[[4-(trifluoromethyl)benzyl]sulfamoyl]]dibenzamide | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.000128 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide) | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00026 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis[[4-(trifluoromethyl)benzyl]sulfamoyl]]dibenzamide | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00026 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis(benzylsulfamoyl)]dibenzamide | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00027 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide) | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00033 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide] | mutant I84V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.00039 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide] | wild-type, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.001 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide) | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0014 | - |
4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis(benzylsulfamoyl)]dibenzamide | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
| 0.0014 | - |
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide] | mutant I50V, pH 5.5 | Human immunodeficiency virus 1 | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
